Technology
AbTis Linker
AbTis next generation linker
Site-specific (Fc region) conjugation using traceless linker
AbTis ADC production by Traceless Linker
(Two simple steps)
- Antibody-FcBP w/ functional group reaction
(FcBP release in this step) - Drug w/functional group Addition (Addition of drug-linker)
AbTis ADC Linker Competitive Edge
Advantage over conventional ADC
Drug Conjugation to the unmodified mAb
- Applicable to the therapeutic antibody with no modification :
Cost-effective ADC production
Site-specific conjugation
-
Covalent bond with Fc-domain
-
High yield of conjugation and simple process of purification: CMC advantage
Diversity of conjugates
-
Drug-loading control (1~4)
-
Diverse drug conjugation / in-vivo diagnostics
Stable in serum, protease-specific drug release linker
-
Peptide linker with serum stability
-
Valine-Citrulline moiety